Min Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Min Zhang has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Yannan Yang
South Australian Immunogenomics Cancer Institute The University of Adelaide Adelaide South Australia Australia
4 shared publications Yiming Huang
Clinical Medicine Scientific and Technical Innovation Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200092, PR China
4 shared publicationsJie Zou
Clinical Medicine Scientific and Technical Innovation Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200092, PR China
3 shared publicationsHuihui Ma
Clinical Medicine Scientific and Technical Innovation Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200092, PR China
2 shared publicationsJiangyan Huo
Clinical Medicine Scientific and Technical Innovation Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200092, PR China
2 shared publicationsXiaoli Yan
Laboratory of Immunology and Pathogen Biology, School of Medicine, Tongji University, Shanghai, 200092, PR China
2 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by Elsevier in Biomaterials
- Vol. 328, 123901
An intermediate-crystalline phase manganese nanoadjuvant potently activates cGAS-STING signaling and antitumor immunity via immunometabolism normalization
- 11 December 2025
- Published by Elsevier in Biomaterials
- Vol. 328, 123901
Open AccessAn intermediate-crystalline phase manganese nanoadjuvant potently activates cGAS-STING signaling and antitumor immunity via immunometabolism normalization
- Open Access
- 6 September 2024
- Published by Elsevier in Chemical Engineering Journal
- Vol. 498
Astragaloside IV microfibers assembling into injectable 3D-scaffolds with intrinsic immunoactivity for enhanced tumor vaccine efficacy
- 6 September 2024
- Published by Elsevier in Chemical Engineering Journal
- Vol. 498
Open AccessAstragaloside IV microfibers assembling into injectable 3D-scaffolds with intrinsic immunoactivity for enhanced tumor vaccine efficacy
- Open Access
- 29 February 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Mesoporous nanoperforators as membranolytic agents via nano- and molecular-scale multi-patterning
Plasma membrane lysis is an effective anticancer strategy, which mostly relying on soluble molecular membranolytic agents. However, nanomaterial-based membranolytic agents has been largely unexplored. Herein, we introduce a mesoporous membranolytic nanoperforators (MLNPs) via a nano- and molecular-scale multi-patterning strategy, featuring a spiky surface topography (nanoscale patterning) and molecular-level periodicity in the spikes with a benzene-bridged organosilica composition (molecular-scale patterning), which cooperatively endow an intrinsic membranolytic activity. Computational modelling reveals a nanospike-mediated multivalent perforation behaviour, i.e., multiple spikes induce nonlinearly enlarged membrane pores compared to a single spike, and that benzene groups aligned parallelly to a phospholipid molecule show considerably higher binding energy than other alignments, underpinning the importance of molecular ordering in phospholipid extraction for membranolysis. Finally, the antitumour activity of MLNPs is demonstrated in female Balb/c mouse models. This work demonstrates assembly of organosilica based bioactive nanostructures, enabling new understandings on nano-/molecular patterns co-governed nano-bio interaction.
- 29 February 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Open AccessMesoporous nanoperforators as membranolytic agents via nano- and molecular-scale multi-patterning
Plasma membrane lysis is an effective anticancer strategy, which mostly relying on soluble molecular membranolytic agents. However, nanomaterial-based membranolytic agents has been largely unexplored. Herein, we introduce a mesoporous membranolytic nanoperforators (MLNPs) via a nano- and molecular-scale multi-patterning strategy, featuring a spiky surface topography (nanoscale patterning) and molecular-level periodicity in the spikes with a benzene-bridged organosilica composition (molecular-scale patterning), which cooperatively endow an intrinsic membranolytic activity. Computational modelling reveals a nanospike-mediated multivalent perforation behaviour, i.e., multiple spikes induce nonlinearly enlarged membrane pores compared to a single spike, and that benzene groups aligned parallelly to a phospholipid molecule show considerably higher binding energy than other alignments, underpinning the importance of molecular ordering in phospholipid extraction for membranolysis. Finally, the antitumour activity of MLNPs is demonstrated in female Balb/c mouse models. This work demonstrates assembly of organosilica based bioactive nanostructures, enabling new understandings on nano-/molecular patterns co-governed nano-bio interaction.
- Open Access
- 21 May 2023
- Published by Wiley in Advanced Science
- Vol. 10 (22) , e2302250
Advanced Oxidation Nanoprocessing Boosts Immunogenicity of Whole Tumor Cells
Whole tumor cells expressing a wide array of tumor antigens are considered as a highly promising source of antigens for cancer vaccines. However, simultaneously preserving the antigen diversity, improving immunogenicity, and eliminating the potential tumorigenic risk of whole tumor cells are highly challenging. Inspired by the recent progress in sulfate radical‐based environmental technology, herein, an advanced oxidation nanoprocessing (AONP) strategy is developed for boosting the immunogenicity of whole tumor cells. The AONP is based on the activation of peroxymonosulfate by ZIF‐67 nanocatalysts to produce SO4−∙ radicals continuously, leading to sustained oxidative damage to tumor cells and consequently extensive cell death. Importantly, AONP causes immunogenic apoptosis as evidenced by the release of a series of characteristic damage associated molecular patterns and at the same time maintains the integrity of cancer cells, which is critical to preserve the cellular components and thus maximize the diversity of antigens. Finally, the immunogenicity of AONP‐treated whole tumor cells is evaluated in a prophylactic vaccination model, demonstrating significantly delayed tumor growth and increased survival rate of live tumor‐cell‐challenged mice. It is expected that the developed AONP strategy would pave the way to develop effective personalized whole tumor cell vaccines in future.
- 21 May 2023
- Published by Wiley in Advanced Science
- Vol. 10 (22) , e2302250
Open AccessAdvanced Oxidation Nanoprocessing Boosts Immunogenicity of Whole Tumor Cells
Whole tumor cells expressing a wide array of tumor antigens are considered as a highly promising source of antigens for cancer vaccines. However, simultaneously preserving the antigen diversity, improving immunogenicity, and eliminating the potential tumorigenic risk of whole tumor cells are highly challenging. Inspired by the recent progress in sulfate radical‐based environmental technology, herein, an advanced oxidation nanoprocessing (AONP) strategy is developed for boosting the immunogenicity of whole tumor cells. The AONP is based on the activation of peroxymonosulfate by ZIF‐67 nanocatalysts to produce SO4−∙ radicals continuously, leading to sustained oxidative damage to tumor cells and consequently extensive cell death. Importantly, AONP causes immunogenic apoptosis as evidenced by the release of a series of characteristic damage associated molecular patterns and at the same time maintains the integrity of cancer cells, which is critical to preserve the cellular components and thus maximize the diversity of antigens. Finally, the immunogenicity of AONP‐treated whole tumor cells is evaluated in a prophylactic vaccination model, demonstrating significantly delayed tumor growth and increased survival rate of live tumor‐cell‐challenged mice. It is expected that the developed AONP strategy would pave the way to develop effective personalized whole tumor cell vaccines in future.